E!167, APTAMER, Icellate Medical AB
| Reference number | |
| Coordinator | Icellate Medical AB |
| Funding from Vinnova | SEK 4 952 450 |
| Project duration | June 2022 - May 2024 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
iCellate has completed development of a new blood-based companion diagnostic test, CellMate® Ewing sarcoma, for the new Ewing sarcoma drug ADEL-101. The new test aims to non-invasively predict treatment safety and efficacy of the ADEL-101 drug for the individual patient by taking samples of individual cancer cells.
Expected long term effects
We judge that the CellMate® Ewing Sarcoma test is ready to be matched against ADEL-101 treatment safety and efficacy in a phase 2 study.
Approach and implementation
The APTAMER project is a near-ideal opportunity to demonstrate the universality and flexibility of the CellMate® oncological in vitro companion diagnostic platform technology for new targeted oncology therapies.